Published : 18 May 2016

---

Bringing success to its clients is the prime focus of Aagami and it has brought another success to its Australian biotechnology client, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY).

On 18 May, POH announced that it has expanded its existing agreement with Themis Medicare Limited, India, for its TPM®/Diclofenac gel, to include an additional 16 geographical markets.

Phosphagenics was advised on this licensing transaction by Aagami.

This is the 4th strategic partnership that Aagami has facilitated for POH, and looks forward to cementing further partnerships soon.